Globeflex Capital’s Capricor Therapeutics CAPR Stock Holding History

Globeflex Capital’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-14	Closed	-$1K	–	485
2016 Q2	$1K	Hold	14	–	–	﹤0.01%	382
2016 Q1	$0	Hold	14	–	–	﹤0.01%	449
2015 Q4	$0	Hold	14	–	–	﹤0.01%	449
2015 Q3	$1K	Buy	+14	New	+$623	﹤0.01%	422

Other funds holding CAPR

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

CBA

Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Apriem Advisors Irvine, California $1.05B AUM 22.09% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

FWM

Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Globeflex Capital's CAPR Position: Q3 2016 in Review

Globeflex Capital sold out of Capricor Therapeutics (CAPR) in Q3 2016, closing a stake of 14 shares — an estimated $1K sold.

Globeflex Capital first reported a position in CAPR in Q3 2015 and held it in 4 quarters. The position peaked at $1K in Q2 2016. 22 funds tracked by Wall St. Rank hold CAPR as of Q3 2016.

Globeflex Capital reported no remaining Capricor Therapeutics position as of Q3 2016 after selling out during the quarter.
Globeflex Capital sold 14 Capricor Therapeutics shares in Q3 2016, an estimated $1K.
Globeflex Capital first reported a position in Capricor Therapeutics in Q3 2015 and held it in 4 quarters.
Globeflex Capital's Capricor Therapeutics position peaked at $1K in Q2 2016.
22 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2016.

Based on Globeflex Capital's 13F filing for Q3 2016, filed 9 Nov 2016.